Head and Neck Cancer Research

Current Projects

• Insulin-like growth factor-1 receptor (IGF1R)-induced resistance to targeted therapy in head and neck squamous cell carcinoma (HNSCC): identifying predictors and determining the utility of IGF1R antagonism
• IGF1R expression in HNSCC as a predictor of sensitivity to adjuvant EGFR inhibition
• Treatment of HNSCC with novel combinations of targeted therapeutics: methods of predicting successful tumor growth inhibition
• Molecular predictors of response to chemoradiotherapy in head and neck squamous cell carcinoma with special focus on impact of HPV infection
• Novel cancer-gonad antigens in head and neck squamous cell carcinoma: determining value as diagnostic biomarkers and/or therapeutic targets
• Nanoliposome-delivered ceramide as a novel therapy for HNSCC
• Interrogation of tumor response to therapy using microsampling and nanoimmunoassay
• Predictors of outcome after major head and neck reconstructive surgery: improving cost-effectiveness and function
• Oncologic, functional and quality of life outcomes after transoral robotic surgery (TORS)
• Utility of adipose-derived stem cells in head and neck reconstruction; impact on behavior of head and neck cancers

Clinical Trials

UVA Head and Neck Innovative Treatment Group / Theraclion
A pilot study to evaluate the feasibility and safety of high intensity focused ultrasound for treatment of papillary thyroid cancer (pending)

Ludwig Institute for Cancer Research LUD2014-011
A phase 1/2 study of in situ vaccination with tremelimumab and IV durvalumab (MEDI4736) plus the Toll-like receptor agonist polyICLC in subjects with advanced, measurable, biopsy-accessible cancers (pending)

Bristol-Myers Squibb BMS CA209-651
An open label, randomized, two arm phase III study of nivolumab in combination with ipilimumab versus extreme study regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first line therapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) (pending)

ECOG-ACRIN #3132
Phase II randomized trial of adjuvant radiotherapy with or without cisplatin for p53 mutated, surgically resected squamous cell carcinoma of the head and neck (SCCHN) (pending)

Merck MK-3475-048, IRB# 18172
A phase 3 clinical trial of pembrolizumab (MK-3475) in first line treatment of recurrent/metastatic head and neck squamous cell carcinoma
10/2015 – present

ECOG-ACRIN #3311, IRB# 17965
Phase II randomized trial of transoral surgical resection followed by low-dose or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer
10/2015 – present

UVA Otolaryngology – Head and Neck Surgery, IRB# 16376
A single arm study of efficacy and functional quality of life in patients treated with transoral robotic surgery for oropharyngeal and supraglottic squamous cell carcinoma
8/2012 – present

UVA Otolaryngology – Head and Neck Surgery, IRB# 14245
Assessment of predictive biomarkers in head and neck squamous cell carcinoma
3/2009-present

National Institute of Dental and Craniofacial Research (NIDCR) / M D Anderson Cancer Center
Tissue bank consortium for salivary gland tumors
8/2008 – present